![]() |
|||
|
|||
Victor Kong, Lutz Beckert, Charles Awunor-Renner
We present a case of a 58-year-old man who experienced
marked visual hallucination as a result of the use of ertapenem.
Case reportMr F is a 58-year-old man who was admitted with episodes of
marked nocturnal visual hallucination, following his recent discharge from the
orthopaedic service some 2 weeks previously for management of a recurrent hip
wound infection following multiple operations for a femoral fracture a year ago.
Multiple resistant organisms were cultured from the wound
and he was commenced on a course of ertapenem and discharged. Post discharge, he
experienced marked nocturnal visual hallucinations on a daily basis. On multiple
occasions, the presence of his close friends was perceived as real and he
engaged in sensible conversation, only to notice their actual absence after a
brief period of time.
Others episodes included seeing text messages on his
switched-off cell phone, and pouring tea into an absent cup, again, noted by the
patient shortly afterwards. These were also well noted by family members and
were initially thought to be generalised “confusions”, to the degree
that the patient was constantly unsure if he was hallucinating or not. He was
not delusional, remained conscious throughout and recalled these episodes in
vivid detail as real events, which caused significant distress to him and the
family.
These symptoms were most marked some 4 hours post dosage of
ertapenem (once daily intravenously administered by the district nurse),
improved the following day and recurred with repeated dosage at approximately
the same time each day. He had no other specific complaints and no psychiatric
history. Relevant medical histories include coeliac disease, osteoporosis and
chronic liver disease. His only other medications were nadalol and alendronate.
On examination he was alert, orientated with no altered
sensorium. No focal neurology was noted and there was no evidence suggestive of
hepatic encephalopathy. A subsequent CT head scan was also unremarkable.
He was managed on the medical ward and continued to
experience daily episodes of visual hallucination obvious to ward staff.
Haloperidol was commenced with no symptomatic improvement despite repeated
dosage. No other causes were found the following week, when psychiatric
consultation was initially contemplated. Ertapenem was eventually suspected and
was withheld for 2 days, when improvement was noticed by the patient. It was
reintroduced at a lower dosage, but almost identical symptoms recurred shortly
thereafter.
Following consultation with the clinical microbiologist, it
was eventually discontinued and changed to amikacin. Marked improvement was
noted and eventually the rapid complete resolution of symptoms. The patient had
no further episodes since and was subsequently discharged.
DiscussionErtapenem is a potent, broad spectrum beta lactam antibiotic
of a sub class known as carbapenem and is commonly used for mixed aerobic and
anaerobic polymicrobial infections.1
Hallucination is a rare adverse event, but generalised altered mental status has
been documented that ranges between 3.3 to
5.1%.2 A case of tactile hallucination has been
report in the United States.3 However, the case
presented here is the only case of nocturnal visual hallucination related to
ertapenem reported to the New Zealand Centre for Adverse Reactions Monitoring to
date.
Mr F experienced marked symptoms on a daily basis shortly
after commencing ertapenem, which occurred at specific time of the day that
appeared to coincide with symtomatology. The subsequent reintroduction resulting
in recurrence of almost identical symptoms, and a complete resolution shortly
after its termination, are highly suggestive of their
association.4
Ertapenem related visual hallucination is a rare but
important adverse effect and is a frightening and difficult experience for the
patient and family. It can be difficult to recognise and may easily be mistaken
as being of non-organic origin. Consequently, a systematic review of
patients’ medications, with consideration for appropriate adjustment, is
of crucial importance.
Author information: Victor Kong, Medical
House Officer, Timaru Hospital, Timaru, South Canterbury; Lutz Beckert, Locum
Consultant Physician, Timaru Hospital, Timaru, South Canterbury—and
Consultant Respiratory Physician, Christchurch Hospital, Christchurch; Charles
Awunor-Renner, Locum Consultant Physician, Timaru Hospital, Timaru, South
Canterbury
Correspondence: Dr Victor Kong, Medical
House Officer, Timaru Hospital,
PO Box 911, Timaru, South Canterbury, New Zealand. Email: victorywkong@yahoo.com References:
|
|||
| Current
issue | Search journal |
Archived issues | Classifieds
| Hotline (free ads) Subscribe | Contribute | Advertise | Contact Us | Copyright | Other Journals |